United Therapeutics (UTHR) Reports In-Line Q4 EPS, Beats on Revenues
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $472.21 -3.52%
EPS Growth %: -10.1%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
OCCI, IPX, ALZN, More
EPS Growth %: -10.1%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.89, in-line with the analyst estimate of $3.89. Revenue for the quarter came in at $464.7 million versus the consensus estimate of $420.9 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
- General Mills (GIS) Tops Q1 EPS by 3c
- BlackBerry shares gain premarket as Q2 results, guidance beat estimates
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
